Sclerosing Agents in the Management of Lymphatic Malformations in Children: A Systematic Review
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Jan 2022 · 1 min read
In brief
In brief
Systematic review of 48 studies spanning 30 years evaluates sclerotherapy outcomes in 886 pediatric lymphatic malformation patients. Overall success rate of 89% with macrocystic lesions responding better than microcystic variants (89% vs 34% resolution). Analysis examines multiple sclerosing agents, dosing strategies, and complication profiles to guide treatment selection.
Written by the GCMD Library team from the article.
Purpose
Sclerotherapy is frequently employed in treating lymphatic malformations (LMs), and multiple agents, practitioners and strategies exist. This review investigates the reported efficacy and safety of sclerosants in the pediatric population.
Methods
Adhering to PRISMA guidelines, multiple databases were queried without linguistic or temporal restriction. Inclusion criteria were patients aged 0-18 exclusively receiving injection sclerotherapy for the treatment of LMs with follow-up data. Data abstracted included agent, dose, anatomic site and key outcome measures including complications (major/minor) and resolution rates (>95% reduction in volume). Critical appraisal was undertaken using the MINORS tool.
Results
Forty-eight studies met the inclusion criteria with a mean MINORS score of 0.65 ± 0.08. Included studies yielded 886 patients, across nearly 30 years. The overall observed rate of success was 89%, with variable follow-up across publications (6 weeks - 10 years). Most reported LMs were macrocystic (82%) and had a higher resolution rate than mixed/microcytic variants (89%, 71%, 34%, p